Supportive bronchodilator therapy to relieve symptoms and reduce the incidence of exacerbations in adult patients with chronic obstructive pulmonary disease (COPD).
Composition and form of release
Main active ingredients: 1 capsule contains 110 μg of indacaterol, which is equivalent to 143 μg of indacaterol maleate, which corresponds to 85 μg of the target dose of release, and 50 μg of glycopyronium, which corresponds to 63 μg of glycopyronium bromide, which is equivalent to 43 μg of the target dose of release.
Auxiliary components: lactose, magnesium stearate.
It is sold in the form of capsules with a transparent yellow lid and a natural transparent body, on which the inscription “IPG110.50” is applied in blue under two blue stripes.
This drug is included in the group of drugs used for obstructive respiratory diseases.
It is a combination of adrenergic and anticholinergic substances.
Indacaterol is a long-acting beta 2-adrenergic receptor agonist once a day. It stimulates intracellular adenylate cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate to cyclic 3 ‘, 5’-adenosine monophosphate. An increase in the concentration of the latter leads to relaxation of the muscles of the bronchi.
When inhaled into the bronchi, the substance has a local effect as a bronchodilator.
Glycopyronium is an inhaled muscarinic receptor antagonist (anticholinergic agent) with a prolonged action for once a day. Its goal is to support bronchodilator therapy for chronic obstructive pulmonary disease. Its mechanism of action is to block the bronchoconstrictive action of acetylcholine in the muscle cells of the airways, which contributes to the expansion of the airways.
This drug is used as a supportive bronchodilator therapy to relieve symptoms and reduce flare-ups in people with chronic obstructive pulmonary disease.
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or to one of the auxiliary components.
Not used in pediatrics.
Application during pregnancy and lactation
This drug is not recommended for pregnant women – only under strict indications determined by the attending physician.
If it is necessary to take the drug during breastfeeding, lactation is suspended.
Method of administration and dosage
Ultibro Breezheiler is used once a day, every day at the same time. If you miss a dose, the next one must be taken as soon as possible. The patient should understand that more than one dose per day should not be taken.
The drug is used by inhalation using an inhaler.
There may be a slight increase in heart rate, blood pressure and an increase in the QTc interval.
The drug is usually well tolerated when used in the recommended doses.
As side effects can be observed:
- upper respiratory tract infections;
- urinary tract infections;
- angioneurotic edema;
- hyperglycemia and diabetes mellitus;
- mental disorders;
- cardiac ischemia;
- atrial fibrillation;
- oropharyngeal pain, including throat irritation,
- paradoxical bronchospasm;
- nose bleed;
- stomach upset;
- dry mouth;
- itching or rash;
- musculoskeletal pain,
- muscle spasm
- pain in the limbs;
- obstruction of the bladder neck and urinary retention;
- general disorders and reactions at the injection site;
- peripheral edema;
If side effects appear, you should interrupt treatment and contact your doctor for help and changes in the treatment process.
Storage conditions and periods
Expiration date – up to 2 years from the production date indicated on the package. Storage periods should not be exceeded.
The storage temperature should not exceed 25 ° C.